Drug Trial Radar · NCT01929629
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914
Last checked: Nov 20, 2026Latest source record: Apr 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Sep 2013
Primary completion
Mar 2014
Study completion Mar 2014
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 28, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and tolerability of orally administered AZD0914 in healthy adult subjects.
Conditions
- Gonococcal (GC) Infection
Interventions
Part ADrug
Single ascending doses
Part BDrug
Single doses food effect. Subjects to receive 2 single doses, one in fed and one in fasted.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Description of the safety profile in terms of adverse events; blood pressure, heart rate and body temperature; electrocardiograms; telemetry; clinical chemistry ; haematology and physical examinationTime frame: From admission on day -1 until follow up. ( Max 16 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.